GenrAb

GenrAb, Inc. is harnessing the power of adaptive human immunity to discover neuroprotective and neurotherapeutic human antibodies. Guided by proprietary immunogenetic models, the company interrogates cerebrospinal fluid from patients with active neurological diseases to gather novel antibodies associated with human disease. Antibodies such as TGM-010 are selected based on their anti-neuronal capabilities and potential to manage neuronal stress to maintain cellular function and survival. Using this unique approach, GenrAb is building a portfolio of patented therapeutic antibodies that could durably reduce disability in patients with neurodegenerative diseases, democratizing access to rare antibodies found only in certain patients with neurological disorders.